Unlike semaglutide (Ozempic/Wegovy), which targets a single receptor (GLP-1), or tirzepatide (Mounjaro/Zepbound), a dual agonist for GLP-1 and GIP receptors, retatrutide goes one step further and acts as a triple agonist targeting GLP-1, GIP and glucagon receptors
Antioxidants (Basel) 8, 430
We're here to help Semaglutide (Wegovy) Injection is used for weight loss and weight maintenance in addition to diet and physical activity in adults, who have: a BMI of 30 kg/m or greater (with obesity) or a BMI of 27 kg/m and less than 30 kg/m (overweight) and weight-related health problems
Nausea is most likely here
FDA Restrictions on Compound GLP-1 Medications This regulatory action follows the FDA's February 2025 declaration that the semaglutide shortage is officially "resolved." For compounded tirzepatide (Zepbound), the deadline was earlier - March 2025